Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083853 | 0.92 | POLB (0.46) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL16727369 | 0.92 | POLB (0.46) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL15199103 | 0.92 | POLB (0.46) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL1768109 | 0.91 | EPHX1 (0.50) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL26763896 | 0.91 | SMN1; SMN2 (0.55) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL24474359 | 0.90 | ROCK2 (0.46) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL17787637 | 0.90 | EPHX1 (0.42) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL10270129 | 0.90 | ROCK2 (0.46) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL26716801 | 0.90 | MMP8 (0.51) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 | |
| SCHEMBL23729169 | 0.90 | ALDH1A1 (0.45) | CYP2D6CYP2C19EPHX1PSMB5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023066348-A1 | DUAL ANTAGONIST AND USE THEREOF | 年衍药业（上海）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023284881-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KRAS G12D INHIBITORS | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-01-19 | — | — | WO | disclosed |
| WO-2021214472-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
| US-20210284640-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | GENENTECH, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2011101402-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CYP2D6 1635/4885CYP2C19 4628/4885EPHX1 2488/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | CYP2D6 720/4885CYP2C19 1431/4885EPHX1 935/4885 |
| US-20210284640-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CYP2D6 1272/4885CYP2C19 4574/4885EPHX1 2131/4885 |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | NQO1, NDUFC2, NDUFV2 | CYP2D6 85/4885CYP2C19 255/4885EPHX1 1522/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | CYP2D6 862/4885CYP2C19 1844/4885EPHX1 1570/4885 |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CYP2D6 1646/4885CYP2C19 4665/4885EPHX1 2496/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | CYP2D6 862/4885CYP2C19 1844/4885EPHX1 1570/4885 |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CYP2D6 2841/4885CYP2C19 2129/4885EPHX1 1719/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | CYP2D6 4506/4885CYP2C19 4589/4885EPHX1 4613/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP2D6 2931/4885CYP2C19 2879/4885EPHX1 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.